Skip to content
Master Your Financial Future — Master Your Money — Financial Headlines — crime-and-justice

ADMA Biologics accused of inflating 2025 sales through distributor stockpiling

A bombshell report accuses ADMA Biologics of channel stuffing—forcing excess inventory on distributors to hide a 3% revenue drop. Now, investors demand answers.

,   and  Administrator
1 min read
The image shows a graph depicting the increased BAA issuance across industry groups. The graph is...
The image shows a graph depicting the increased BAA issuance across industry groups. The graph is accompanied by text that provides further information about the data.

ADMA Biologics accused of inflating 2025 sales through distributor stockpiling

ADMA Biologics is facing scrutiny over claims it artificially boosted its 2025 sales figures. A recent report by Culper Research accused the company of pressuring distributors to stockpile its drug ASCENIV. The allegations suggest this tactic was used to inflate reported revenue growth by 20% instead of showing an actual decline. On 24 March 2026, Culper Research released findings that ADMA Biologics had engaged in channel stuffing—a practice where companies push excess inventory onto distributors to meet short-term sales targets. The report claimed this scheme allowed the firm to report a 20% increase in revenue for 2025, masking what would have been a 3% drop.

Law firm Lowey Dannenberg P.C. has since launched an investigation into potential securities law violations by ADMA Biologics. The firm is also representing investors who lost more than $50,000 each on the company’s shares. The probe will examine whether the company misled shareholders about its financial performance.

The allegations centre on ADMA Biologics’ 2025 revenue reporting, with claims that distributor stockpiling created a false picture of growth. Investors who suffered significant losses are now seeking legal action, while regulators may review the company’s compliance with securities laws.

Read also:

Related

Latest